B
Abbott Laboratories
ABT
$133.60
-$4.11-2.99%
B
Buy
2/24/2025Upgraded
Abbott Laboratories (ABT) was upgraded to B- from C+ on 2/24/2025 due to a substantial increase in the valuation index, volatility index and efficiency index. Net income increased 460.69% from $1.65B to $9.23B, and total capital increased 14.71% from $55.07B to $63.18B.
Abbott Laboratories (ABT) was upgraded to B- from C+ on 2/24/2025 due to a substantial increase in the valuation index, volatility index and efficiency index. Net income increased 460.69% from $1.65B to $9.23B, and total capital increased 14.71% from $55.07B to $63.18B.
C
Hold
1/23/2025Upgraded
Abbott Laboratories (ABT) was upgraded to C+ from C on 1/23/2025 due to an increase in the volatility index, total return index and valuation index.
Abbott Laboratories (ABT) was upgraded to C+ from C on 1/23/2025 due to an increase in the volatility index, total return index and valuation index.
C
Hold
9/30/2024Downgrade
Abbott Laboratories (ABT) was downgraded to C from C+ on 9/30/2024 due to a decline in the volatility index.
Abbott Laboratories (ABT) was downgraded to C from C+ on 9/30/2024 due to a decline in the volatility index.
C
Hold
9/13/2024Upgraded
Abbott Laboratories (ABT) was upgraded to C+ from C on 9/13/2024 due to a significant increase in the growth index, total return index and solvency index. Operating cash flow increased 91.22% from $1.03B to $1.96B, EBIT increased 19.41% from $1.54B to $1.83B, and the quick ratio increased from 0.95 to 1.02.
Abbott Laboratories (ABT) was upgraded to C+ from C on 9/13/2024 due to a significant increase in the growth index, total return index and solvency index. Operating cash flow increased 91.22% from $1.03B to $1.96B, EBIT increased 19.41% from $1.54B to $1.83B, and the quick ratio increased from 0.95 to 1.02.
C
Hold
5/3/2024Downgrade
Abbott Laboratories (ABT) was downgraded to C from C+ on 5/3/2024 due to a significant decline in the growth index, total return index and solvency index. Operating cash flow declined 66.26% from $3.04B to $1.03B, EBIT declined 25.38% from $2.06B to $1.54B, and earnings per share declined from $0.9085 to $0.7.
Abbott Laboratories (ABT) was downgraded to C from C+ on 5/3/2024 due to a significant decline in the growth index, total return index and solvency index. Operating cash flow declined 66.26% from $3.04B to $1.03B, EBIT declined 25.38% from $2.06B to $1.54B, and earnings per share declined from $0.9085 to $0.7.
C
Hold
2/15/2024Upgraded
Abbott Laboratories (ABT) was upgraded to C+ from C on 2/15/2024 due to an increase in the volatility index, total return index and solvency index. Debt to equity declined from 0.46 to 0.42, and the quick ratio increased from 1 to 1.04.
Abbott Laboratories (ABT) was upgraded to C+ from C on 2/15/2024 due to an increase in the volatility index, total return index and solvency index. Debt to equity declined from 0.46 to 0.42, and the quick ratio increased from 1 to 1.04.
C
Hold
8/8/2023Downgrade
Abbott Laboratories (ABT) was downgraded to C from C+ on 8/8/2023 due to a decline in the valuation index, efficiency index and growth index. EBIT declined 0.89% from $1.68B to $1.66B.
Abbott Laboratories (ABT) was downgraded to C from C+ on 8/8/2023 due to a decline in the valuation index, efficiency index and growth index. EBIT declined 0.89% from $1.68B to $1.66B.
C
Hold
6/23/2023Upgraded
Abbott Laboratories (ABT) was upgraded to C+ from C on 6/23/2023 due to an increase in the total return index and volatility index.
Abbott Laboratories (ABT) was upgraded to C+ from C on 6/23/2023 due to an increase in the total return index and volatility index.
C
Hold
6/7/2023Downgrade
Abbott Laboratories (ABT) was downgraded to C from C+ on 6/7/2023 due to a large decline in the growth index, valuation index and total return index. Operating cash flow declined 50.86% from $2.33B to $1.14B, and total revenue declined 3.41% from $10.09B to $9.75B.
Abbott Laboratories (ABT) was downgraded to C from C+ on 6/7/2023 due to a large decline in the growth index, valuation index and total return index. Operating cash flow declined 50.86% from $2.33B to $1.14B, and total revenue declined 3.41% from $10.09B to $9.75B.
C
Hold
2/8/2023Upgraded
Abbott Laboratories (ABT) was upgraded to C+ from C on 2/8/2023 due to an increase in the volatility index and efficiency index.
Abbott Laboratories (ABT) was upgraded to C+ from C on 2/8/2023 due to an increase in the volatility index and efficiency index.
C
Hold
9/30/2022Downgrade
Abbott Laboratories (ABT) was downgraded to C from C+ on 9/30/2022 due to a decline in the volatility index and total return index.
Abbott Laboratories (ABT) was downgraded to C from C+ on 9/30/2022 due to a decline in the volatility index and total return index.
C
Hold
9/9/2022Downgrade
Abbott Laboratories (ABT) was downgraded to C+ from B- on 9/9/2022 due to a decline in the total return index and volatility index.
Abbott Laboratories (ABT) was downgraded to C+ from B- on 9/9/2022 due to a decline in the total return index and volatility index.
B
Buy
8/25/2022Upgraded
Abbott Laboratories (ABT) was upgraded to B- from C+ on 8/25/2022 due to an increase in the total return index, valuation index and efficiency index. Total capital increased 1.52% from $52.75B to $53.56B.
Abbott Laboratories (ABT) was upgraded to B- from C+ on 8/25/2022 due to an increase in the total return index, valuation index and efficiency index. Total capital increased 1.52% from $52.75B to $53.56B.
C
Hold
7/18/2022Downgrade
Abbott Laboratories (ABT) was downgraded to C+ from B- on 7/18/2022 due to a decline in the volatility index, total return index and valuation index.
Abbott Laboratories (ABT) was downgraded to C+ from B- on 7/18/2022 due to a decline in the volatility index, total return index and valuation index.
B
Buy
7/1/2022Upgraded
Abbott Laboratories (ABT) was upgraded to B- from C+ on 7/1/2022 due to an increase in the volatility index, valuation index and dividend index.
Abbott Laboratories (ABT) was upgraded to B- from C+ on 7/1/2022 due to an increase in the volatility index, valuation index and dividend index.
C
Hold
6/16/2022Downgrade
Abbott Laboratories (ABT) was downgraded to C+ from B- on 6/16/2022 due to a decline in the volatility index and total return index.
Abbott Laboratories (ABT) was downgraded to C+ from B- on 6/16/2022 due to a decline in the volatility index and total return index.
B
Buy
6/10/2022Downgrade
Abbott Laboratories (ABT) was downgraded to B- from B on 6/10/2022 due to a large decline in the volatility index, total return index and efficiency index. Total capital declined 4.56% from $55.28B to $52.75B.
Abbott Laboratories (ABT) was downgraded to B- from B on 6/10/2022 due to a large decline in the volatility index, total return index and efficiency index. Total capital declined 4.56% from $55.28B to $52.75B.
B
Buy
4/19/2022Downgrade
Abbott Laboratories (ABT) was downgraded to B from B+ on 4/19/2022 due to a decline in the volatility index and total return index.
Abbott Laboratories (ABT) was downgraded to B from B+ on 4/19/2022 due to a decline in the volatility index and total return index.
B
Buy
2/23/2022Downgrade
Abbott Laboratories (ABT) was downgraded to B+ from A- on 2/23/2022 due to a substantial decline in the total return index, growth index and efficiency index. Net income declined 5.29% from $2.1B to $1.99B, and earnings per share declined from $1.17 to $1.1107.
Abbott Laboratories (ABT) was downgraded to B+ from A- on 2/23/2022 due to a substantial decline in the total return index, growth index and efficiency index. Net income declined 5.29% from $2.1B to $1.99B, and earnings per share declined from $1.17 to $1.1107.
A
Buy
2/11/2022Upgraded
Abbott Laboratories (ABT) was upgraded to A- from B on 2/11/2022 due to a major increase in the total return index.
Abbott Laboratories (ABT) was upgraded to A- from B on 2/11/2022 due to a major increase in the total return index.
B
Buy
2/7/2022Downgrade
Abbott Laboratories (ABT) was downgraded to B from B+ on 2/7/2022 due to a major decline in the total return index.
Abbott Laboratories (ABT) was downgraded to B from B+ on 2/7/2022 due to a major decline in the total return index.
B
Buy
1/26/2022Downgrade
Abbott Laboratories (ABT) was downgraded to B+ from A- on 1/26/2022 due to a noticeable decline in the total return index.
Abbott Laboratories (ABT) was downgraded to B+ from A- on 1/26/2022 due to a noticeable decline in the total return index.
A
Buy
1/11/2022Upgraded
Abbott Laboratories (ABT) was upgraded to A- from B+ on 1/11/2022 due to a noticeable increase in the total return index.
Abbott Laboratories (ABT) was upgraded to A- from B+ on 1/11/2022 due to a noticeable increase in the total return index.
B
Buy
12/23/2021Downgrade
Abbott Laboratories (ABT) was downgraded to B+ from A- on 12/23/2021 due to a decline in the total return index, valuation index and dividend index.
Abbott Laboratories (ABT) was downgraded to B+ from A- on 12/23/2021 due to a decline in the total return index, valuation index and dividend index.
A
Buy
12/8/2021Upgraded
Abbott Laboratories (ABT) was upgraded to A- from B+ on 12/8/2021 due to an increase in the total return index and volatility index.
Abbott Laboratories (ABT) was upgraded to A- from B+ on 12/8/2021 due to an increase in the total return index and volatility index.
B
Buy
11/23/2021Downgrade
Abbott Laboratories (ABT) was downgraded to B+ from A- on 11/23/2021 due to a decline in the total return index, volatility index and valuation index.
Abbott Laboratories (ABT) was downgraded to B+ from A- on 11/23/2021 due to a decline in the total return index, volatility index and valuation index.
A
Buy
11/8/2021Upgraded
Abbott Laboratories (ABT) was upgraded to A- from B+ on 11/8/2021 due to a noticeable increase in the growth index, valuation index and efficiency index. Earnings per share increased from $0.66 to $1.17, net income increased 76.62% from $1.19B to $2.1B, and EBIT increased 32.69% from $1.97B to $2.61B.
Abbott Laboratories (ABT) was upgraded to A- from B+ on 11/8/2021 due to a noticeable increase in the growth index, valuation index and efficiency index. Earnings per share increased from $0.66 to $1.17, net income increased 76.62% from $1.19B to $2.1B, and EBIT increased 32.69% from $1.97B to $2.61B.
B
Buy
11/5/2021Upgraded
Abbott Laboratories (ABT) was upgraded to B+ from B on 11/5/2021 due to a significant increase in the total return index, growth index and solvency index. The quick ratio increased from 1.16 to 1.19.
Abbott Laboratories (ABT) was upgraded to B+ from B on 11/5/2021 due to a significant increase in the total return index, growth index and solvency index. The quick ratio increased from 1.16 to 1.19.
B
Buy
5/25/2021Downgrade
Abbott Laboratories (ABT) was downgraded to B from B+ on 5/25/2021 due to a substantial decline in the total return index and volatility index.
Abbott Laboratories (ABT) was downgraded to B from B+ on 5/25/2021 due to a substantial decline in the total return index and volatility index.
B
Buy
5/10/2021Upgraded
Abbott Laboratories (ABT) was upgraded to B+ from B on 5/10/2021 due to a noticeable increase in the valuation index, total return index and efficiency index.
Abbott Laboratories (ABT) was upgraded to B+ from B on 5/10/2021 due to a noticeable increase in the valuation index, total return index and efficiency index.
B
Buy
5/4/2021Downgrade
Abbott Laboratories (ABT) was downgraded to B from B+ on 5/4/2021 due to a decline in the total return index and valuation index.
Abbott Laboratories (ABT) was downgraded to B from B+ on 5/4/2021 due to a decline in the total return index and valuation index.
B
Buy
4/15/2021Upgraded
Abbott Laboratories (ABT) was upgraded to B+ from B on 4/15/2021 due to an increase in the total return index.
Abbott Laboratories (ABT) was upgraded to B+ from B on 4/15/2021 due to an increase in the total return index.
B
Buy
3/31/2021Downgrade
Abbott Laboratories (ABT) was downgraded to B from B+ on 3/31/2021 due to a decline in the total return index and valuation index.
Abbott Laboratories (ABT) was downgraded to B from B+ on 3/31/2021 due to a decline in the total return index and valuation index.
B
Buy
3/15/2021Upgraded
Abbott Laboratories (ABT) was upgraded to B+ from B on 3/15/2021 due to a noticeable increase in the valuation index, efficiency index and volatility index. Net income increased 75.49% from $1.23B to $2.16B, and total capital increased 5.45% from $50.16B to $52.89B.
Abbott Laboratories (ABT) was upgraded to B+ from B on 3/15/2021 due to a noticeable increase in the valuation index, efficiency index and volatility index. Net income increased 75.49% from $1.23B to $2.16B, and total capital increased 5.45% from $50.16B to $52.89B.
B
Buy
2/16/2021Upgraded
Abbott Laboratories (ABT) was upgraded to B from B- on 2/16/2021 due to a large increase in the total return index, growth index and efficiency index.
Abbott Laboratories (ABT) was upgraded to B from B- on 2/16/2021 due to a large increase in the total return index, growth index and efficiency index.
B
Buy
1/27/2021Downgrade
Abbott Laboratories (ABT) was downgraded to B- from B on 1/27/2021 due to a large decline in the total return index and valuation index.
Abbott Laboratories (ABT) was downgraded to B- from B on 1/27/2021 due to a large decline in the total return index and valuation index.
B
Buy
11/9/2020Upgraded
Abbott Laboratories (ABT) was upgraded to B from B- on 11/9/2020 due to a large increase in the growth index, total return index and solvency index. Earnings per share increased from $0.3 to $0.69, EBIT increased 99.04% from $727M to $1.45B, and operating cash flow increased 56.28% from $1.32B to $2.07B.
Abbott Laboratories (ABT) was upgraded to B from B- on 11/9/2020 due to a large increase in the growth index, total return index and solvency index. Earnings per share increased from $0.3 to $0.69, EBIT increased 99.04% from $727M to $1.45B, and operating cash flow increased 56.28% from $1.32B to $2.07B.
B
Buy
8/20/2020Downgrade
Abbott Laboratories (ABT) was downgraded to B- from B on 8/20/2020 due to a noticeable decline in the growth index, volatility index and valuation index. EBIT declined 13.25% from $838M to $727M, total revenue declined 5.15% from $7.73B to $7.33B, and earnings per share declined from $0.3112 to $0.3.
Abbott Laboratories (ABT) was downgraded to B- from B on 8/20/2020 due to a noticeable decline in the growth index, volatility index and valuation index. EBIT declined 13.25% from $838M to $727M, total revenue declined 5.15% from $7.73B to $7.33B, and earnings per share declined from $0.3112 to $0.3.
B
Buy
10/11/2019Downgrade
Abbott Laboratories (ABT) was downgraded to B from B+ on 10/11/2019 due to a noticeable decline in the total return index.
Abbott Laboratories (ABT) was downgraded to B from B+ on 10/11/2019 due to a noticeable decline in the total return index.
B
Buy
9/26/2019Upgraded
Abbott Laboratories (ABT) was upgraded to B+ from B on 9/26/2019 due to a major increase in the growth index, volatility index and solvency index. EBIT increased 51.68% from $832M to $1.26B, operating cash flow increased 48.88% from $712M to $1.06B, and earnings per share increased from $0.3788 to $0.56.
Abbott Laboratories (ABT) was upgraded to B+ from B on 9/26/2019 due to a major increase in the growth index, volatility index and solvency index. EBIT increased 51.68% from $832M to $1.26B, operating cash flow increased 48.88% from $712M to $1.06B, and earnings per share increased from $0.3788 to $0.56.
B
Buy
2/25/2019Upgraded
Abbott Laboratories (ABT) was upgraded to B from C on 2/25/2019 due to a significant increase in the growth index, valuation index and volatility index. EBIT increased 22.61% from $995M to $1.22B, earnings per share increased from $0.3162 to $0.3658, and total revenue increased 1.42% from $7.66B to $7.77B.
Abbott Laboratories (ABT) was upgraded to B from C on 2/25/2019 due to a significant increase in the growth index, valuation index and volatility index. EBIT increased 22.61% from $995M to $1.22B, earnings per share increased from $0.3162 to $0.3658, and total revenue increased 1.42% from $7.66B to $7.77B.
C
Hold
2/20/2018Downgrade
Abbott Laboratories (ABT) was downgraded to C from B on 2/20/2018 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.3439 to -$0.4794, and net income declined 237.31% from $603M to -$828M.
Abbott Laboratories (ABT) was downgraded to C from B on 2/20/2018 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.3439 to -$0.4794, and net income declined 237.31% from $603M to -$828M.
B
Buy
2/15/2018Upgraded
Abbott Laboratories (ABT) was upgraded to B from B- on 2/15/2018 due to an increase in the valuation index and dividend index.
Abbott Laboratories (ABT) was upgraded to B from B- on 2/15/2018 due to an increase in the valuation index and dividend index.
B
Buy
1/31/2018Downgrade
Abbott Laboratories (ABT) was downgraded to B- from B on 1/31/2018 due to a decline in the volatility index, valuation index and dividend index.
Abbott Laboratories (ABT) was downgraded to B- from B on 1/31/2018 due to a decline in the volatility index, valuation index and dividend index.
B
Buy
11/3/2017Upgraded
Abbott Laboratories (ABT) was upgraded to B from C on 11/3/2017 due to a significant increase in the growth index, total return index and valuation index. Earnings per share increased from $0.1574 to $0.3439, EBIT increased 94.38% from $427M to $830M, and operating cash flow increased 48.41% from $1.35B to $2.01B.
Abbott Laboratories (ABT) was upgraded to B from C on 11/3/2017 due to a significant increase in the growth index, total return index and valuation index. Earnings per share increased from $0.1574 to $0.3439, EBIT increased 94.38% from $427M to $830M, and operating cash flow increased 48.41% from $1.35B to $2.01B.
C
Hold
11/4/2016Downgrade
Abbott Laboratories (ABT) was downgraded to C from B- on 11/4/2016 due to a large decline in the valuation index, growth index and total return index. Earnings per share declined from $0.4105 to -$0.2228, and total revenue declined 0.58% from $5.33B to $5.3B.
Abbott Laboratories (ABT) was downgraded to C from B- on 11/4/2016 due to a large decline in the valuation index, growth index and total return index. Earnings per share declined from $0.4105 to -$0.2228, and total revenue declined 0.58% from $5.33B to $5.3B.
B
Buy
10/28/2016Upgraded
Abbott Laboratories (ABT) was upgraded to B- from C on 10/28/2016 due to a large increase in the valuation index, growth index and efficiency index. Operating cash flow increased 1,077.42% from -$93M to $909M, net income increased 94.62% from $316M to $615M, and earnings per share increased from $0.2139 to $0.4108.
Abbott Laboratories (ABT) was upgraded to B- from C on 10/28/2016 due to a large increase in the valuation index, growth index and efficiency index. Operating cash flow increased 1,077.42% from -$93M to $909M, net income increased 94.62% from $316M to $615M, and earnings per share increased from $0.2139 to $0.4108.
C
Hold
10/20/2016Downgrade
Abbott Laboratories (ABT) was downgraded to C from B- on 10/20/2016 due to a large decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.4108 to -$0.2229, net income declined 153.5% from $615M to -$329M, and total revenue declined 0.58% from $5.33B to $5.3B.
Abbott Laboratories (ABT) was downgraded to C from B- on 10/20/2016 due to a large decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.4108 to -$0.2229, net income declined 153.5% from $615M to -$329M, and total revenue declined 0.58% from $5.33B to $5.3B.
B
Buy
9/26/2016Upgraded
Abbott Laboratories (ABT) was upgraded to B- from C+ on 9/26/2016 due to an increase in the volatility index, total return index and valuation index.
Abbott Laboratories (ABT) was upgraded to B- from C+ on 9/26/2016 due to an increase in the volatility index, total return index and valuation index.
C
Hold
8/24/2016Upgraded
Abbott Laboratories (ABT) was upgraded to C+ from C on 8/24/2016 due to a major increase in the growth index and volatility index. Operating cash flow increased 1,077.42% from -$93M to $909M, earnings per share increased from $0.2139 to $0.4108, and EBIT increased 39.97% from $583M to $816M.
Abbott Laboratories (ABT) was upgraded to C+ from C on 8/24/2016 due to a major increase in the growth index and volatility index. Operating cash flow increased 1,077.42% from -$93M to $909M, earnings per share increased from $0.2139 to $0.4108, and EBIT increased 39.97% from $583M to $816M.
C
Hold
5/6/2016Downgrade
Abbott Laboratories (ABT) was downgraded to C from C+ on 5/6/2016 due to a substantial decline in the valuation index, growth index and solvency index. Operating cash flow declined 111.23% from $828M to -$93M, earnings per share declined from $0.5079 to $0.2139, and EBIT declined 37.06% from $858M to $540M.
Abbott Laboratories (ABT) was downgraded to C from C+ on 5/6/2016 due to a substantial decline in the valuation index, growth index and solvency index. Operating cash flow declined 111.23% from $828M to -$93M, earnings per share declined from $0.5079 to $0.2139, and EBIT declined 37.06% from $858M to $540M.
C
Hold
3/11/2016Downgrade
Abbott Laboratories (ABT) was downgraded to C+ from B- on 3/11/2016 due to a noticeable decline in the total return index, growth index and volatility index. Operating cash flow declined 30.71% from $1.2B to $828M.
Abbott Laboratories (ABT) was downgraded to C+ from B- on 3/11/2016 due to a noticeable decline in the total return index, growth index and volatility index. Operating cash flow declined 30.71% from $1.2B to $828M.
B
Buy
10/30/2015Downgrade
Abbott Laboratories (ABT) was downgraded to B- from B on 10/30/2015 due to a decline in the total return index.
Abbott Laboratories (ABT) was downgraded to B- from B on 10/30/2015 due to a decline in the total return index.
B
Buy
9/15/2015Upgraded
Abbott Laboratories (ABT) was upgraded to B from B- on 9/15/2015 due to an increase in the valuation index and dividend index.
Abbott Laboratories (ABT) was upgraded to B from B- on 9/15/2015 due to an increase in the valuation index and dividend index.
B
Buy
8/21/2015Downgrade
Abbott Laboratories (ABT) was downgraded to B- from B on 8/21/2015 due to a decline in the total return index and volatility index.
Abbott Laboratories (ABT) was downgraded to B- from B on 8/21/2015 due to a decline in the total return index and volatility index.
B
Buy
8/6/2015Upgraded
Abbott Laboratories (ABT) was upgraded to B from B- on 8/6/2015 due to an increase in the growth index, volatility index and solvency index. Operating cash flow increased 46,950% from $2M to $941M, EBIT increased 11.47% from $654M to $729M, and the quick ratio increased from 1.45 to 1.6.
Abbott Laboratories (ABT) was upgraded to B from B- on 8/6/2015 due to an increase in the growth index, volatility index and solvency index. Operating cash flow increased 46,950% from $2M to $941M, EBIT increased 11.47% from $654M to $729M, and the quick ratio increased from 1.45 to 1.6.
B
Buy
5/8/2015Upgraded
Abbott Laboratories (ABT) was upgraded to B- from C+ on 5/8/2015 due to a major increase in the valuation index, total return index and efficiency index. Net income increased 153.54% from $904M to $2.29B, and total capital increased 4.77% from $29.48B to $30.89B.
Abbott Laboratories (ABT) was upgraded to B- from C+ on 5/8/2015 due to a major increase in the valuation index, total return index and efficiency index. Net income increased 153.54% from $904M to $2.29B, and total capital increased 4.77% from $29.48B to $30.89B.
C
Hold
2/27/2015Upgraded
Abbott Laboratories (ABT) was upgraded to C+ from C on 2/27/2015 due to an increase in the valuation index, total return index and efficiency index. Net income increased 68.03% from $538M to $904M.
Abbott Laboratories (ABT) was upgraded to C+ from C on 2/27/2015 due to an increase in the valuation index, total return index and efficiency index. Net income increased 68.03% from $538M to $904M.
C
Hold
1/26/2015Downgrade
Abbott Laboratories (ABT) was downgraded to C from C+ on 1/26/2015 due to a noticeable decline in the valuation index, solvency index and total return index. The quick ratio declined from 1.13 to 0.78, and debt to equity increased from 0.31 to 0.36.
Abbott Laboratories (ABT) was downgraded to C from C+ on 1/26/2015 due to a noticeable decline in the valuation index, solvency index and total return index. The quick ratio declined from 1.13 to 0.78, and debt to equity increased from 0.31 to 0.36.
C
Hold
8/7/2014Upgraded
Abbott Laboratories (ABT) was upgraded to C+ from C on 8/7/2014 due to a noticeable increase in the total return index, solvency index and growth index. Operating cash flow increased 167.86% from $336M to $900M, EBIT increased 36.87% from $556M to $761M, and earnings per share increased from $0.2433 to $0.304.
Abbott Laboratories (ABT) was upgraded to C+ from C on 8/7/2014 due to a noticeable increase in the total return index, solvency index and growth index. Operating cash flow increased 167.86% from $336M to $900M, EBIT increased 36.87% from $556M to $761M, and earnings per share increased from $0.2433 to $0.304.
NYSE
03/06/2025 1:42PM Eastern
Quotes delayed
